SRR1467212
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.347
- ANGIOGENESIS+0.340
- KRAS_SIGNALING_DN+0.304
- INFLAMMATORY_RESPONSE+0.295
- APICAL_SURFACE+0.274
- CHOLESTEROL_HOMEOSTASIS+0.191
- APICAL_JUNCTION+0.186
- COAGULATION+0.164
- COMPLEMENT+0.162
- KRAS_SIGNALING_UP+0.157
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.669
- MYC_TARGETS_V1-0.582
- MYC_TARGETS_V2-0.535
- UNFOLDED_PROTEIN_RESPONSE-0.495
- DNA_REPAIR-0.489
- E2F_TARGETS-0.418
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.402
- MTORC1_SIGNALING-0.397
- G2M_CHECKPOINT-0.375
- PI3K_AKT_MTOR_SIGNALING-0.328
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1312743 | GTEX | — | 0.935 |
| 2 | SRR1325964 | GTEX | — | 0.917 |
| 3 | SRR1480307 | GTEX | — | 0.903 |
| 4 | SRR1095865 | GTEX | — | 0.893 |
| 5 | MNG298 | — | — | 0.893 |
| 6 | SRR1321674 | GTEX | — | 0.889 |
| 7 | SRR1370797 | GTEX | — | 0.888 |
| 8 | SRR612563 | GTEX | — | 0.885 |
| 9 | SRR1475803 | GTEX | — | 0.884 |
| 10 | SRR1362464 | GTEX | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.347 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.304 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.295 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.274 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.191 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.186 | Inavolisib | — uncovered |
| COAGULATION | 0.164 | Binimetinib | — uncovered |
| COMPLEMENT | 0.162 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.157 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.152 | Inavolisib | — uncovered |
| MYOGENESIS | 0.139 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.111 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.111 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.076 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.056 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.042 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.029 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.019 | Idelalisib | — uncovered |